Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Rating) Director James L. L. Tullis bought 7,500 shares of the stock in a transaction on Wednesday, June 15th. The stock was purchased at an average cost of $6.76 per share, for a total transaction of $50,700.00. Following the acquisition, the director now directly owns 187,558 shares of the company’s stock, valued at approximately $1,267,892.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of NASDAQ:ATEC opened at $6.79 on Thursday. The stock’s 50-day moving average price is $9.48 and its two-hundred day moving average price is $10.54. The company has a current ratio of 2.62, a quick ratio of 1.76 and a debt-to-equity ratio of 7.78. Alphatec Holdings, Inc. has a 12-month low of $6.61 and a 12-month high of $16.47. The firm has a market cap of $690.94 million, a price-to-earnings ratio of -4.12 and a beta of 1.59.
Alphatec (NASDAQ:ATEC – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The medical technology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.14). Alphatec had a negative return on equity of 147.10% and a negative net margin of 60.83%. The firm had revenue of $70.93 million during the quarter, compared to analysts’ expectations of $67.72 million. As a group, research analysts forecast that Alphatec Holdings, Inc. will post -1.31 earnings per share for the current fiscal year.
A number of analysts recently commented on the company. HC Wainwright increased their price objective on Alphatec from $19.00 to $20.00 in a research note on Friday, May 6th. Piper Sandler decreased their price objective on Alphatec from $22.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 2nd. StockNews.com assumed coverage on Alphatec in a research note on Thursday, March 31st. They set a “sell” rating on the stock. Finally, Needham & Company LLC decreased their price objective on Alphatec from $15.00 to $13.00 and set a “buy” rating on the stock in a research note on Thursday, May 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Alphatec has a consensus rating of “Buy” and an average target price of $18.71.
Alphatec Company Profile (Get Rating)
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement.
- Get a free copy of the StockNews.com research report on Alphatec (ATEC)
- Commercial Metals Company Is Ready To Rebound
- The Institutions Turn The Tide For Jabil
- A10 Networks: Key 5G Infrastructure Stock that’s Beating the Market
- Allstate: A Safe Stock During Volatile Times, Which Will Benefit From Rising Rates
- Wix.com Stock Nearing a Bottom Wick
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.